PubRank

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

Clinical Trial ID NCT01522443

PubWeight™ 30.53‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01522443

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012 1.81
2 Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014 1.70
3 A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013 1.33
4 Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol 2013 1.17
5 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
6 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014 1.11
7 Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014 1.10
8 Tumor stroma as targets for cancer therapy. Pharmacol Ther 2012 1.06
9 Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013 1.00
10 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
11 Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014 0.97
12 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
13 New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2012 0.95
14 Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev 2014 0.92
15 Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol 2015 0.92
16 Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol 2012 0.91
17 Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer 2013 0.91
18 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
19 Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 2014 0.86
20 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
21 Biomarker development in the context of urologic cancers. Urol Oncol 2015 0.81
22 Bone-targeting agents in prostate cancer. Cancer Metastasis Rev 2014 0.80
23 Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014 0.80
24 The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res 2015 0.79
25 Met in urological cancers. Cancers (Basel) 2014 0.77
26 Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl 2014 0.77
27 Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis. Am J Clin Exp Urol 2013 0.77
28 Abiraterone acetate: a hat trick of clinical benefits. Lancet Oncol 2012 0.76
29 A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res 2015 0.76
30 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
31 Development of cabozantinib for the treatment of prostate cancer. Core Evid 2014 0.75
32 Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci 2016 0.75
33 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
Next 100